Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.82 -1.86% -0.02
LCTX closed down 1.86 percent on Friday, November 1, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 7
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -1.86%

   Recent Intraday Alerts

Alert Time
Outside Day about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago
Down 1% about 19 hours ago
Rose Above Previous Day's High about 22 hours ago
20 DMA Resistance about 22 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lineage Cell Therapeutics, Inc. Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Immunotherapy Stem Cell Cell Therapy Non Small Cell Lung Cancer Drug Delivery Human Diseases Osteoarthritis Degenerative Disease Regenerative Medicine Advanced Therapy Stem Cell Therapy Dry Age Related Macular Degeneration Lineage Cell Therapeutics

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.61
52 Week Low 0.7665
Average Volume 395,631
200-Day Moving Average 1.02
50-Day Moving Average 0.88
20-Day Moving Average 0.86
10-Day Moving Average 0.86
Average True Range 0.05
RSI (14) 41.52
ADX 10.43
+DI 15.19
-DI 20.07
Chandelier Exit (Long, 3 ATRs) 0.80
Chandelier Exit (Short, 3 ATRs) 0.92
Upper Bollinger Bands 0.90
Lower Bollinger Band 0.82
Percent B (%b) -0.02
BandWidth 10.11
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0033
Fundamentals Value
Market Cap 153.76 Million
Num Shares 188 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -6.28
Price-to-Sales 23.21
Price-to-Book 2.99
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.90
Resistance 3 (R3) 0.91 0.89 0.89
Resistance 2 (R2) 0.89 0.87 0.88 0.88
Resistance 1 (R1) 0.85 0.85 0.84 0.84 0.88
Pivot Point 0.83 0.83 0.83 0.83 0.83
Support 1 (S1) 0.80 0.81 0.78 0.79 0.76
Support 2 (S2) 0.77 0.80 0.77 0.75
Support 3 (S3) 0.74 0.77 0.75
Support 4 (S4) 0.73